Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;11(5):289-98.
doi: 10.1111/j.1468-1293.2009.00776.x. Epub 2009 Dec 8.

Hospitalization risk following initiation of highly active antiretroviral therapy

S A Berry  1 , Y C Manabe, R D Moore, K A Gebo
Affiliations

Hospitalization risk following initiation of highly active antiretroviral therapy

S A Berry et al. HIV Med. 2010 May.

Abstract

Objectives: While highly active antiretroviral therapy (HAART) decreases long-term morbidity and mortality, its short-term effect on hospitalization rates is unknown. The primary objective of this study was to determine hospitalization rates over time in the year after HAART initiation for virological responders and nonresponders.

Methods: Hospitalizations among 1327 HAART-naïve subjects in an urban HIV clinic in 1997-2007 were examined before and after HAART initiation. Hospitalization rates were stratified by virological responders (> or =1 log(10) decrease in HIV-1 RNA within 6 months after HAART initiation) and nonresponders. Causes were determined through International Classification of Diseases, 9th Revision (ICD-9) codes and chart review. Multivariate negative binomial regression was used to assess factors associated with hospitalization.

Results: During the first 45 days after HAART initiation, the hospitalization rate of responders was similar to their pre-HAART baseline rate [75.1 vs. 78.8/100 person-years (PY)] and to the hospitalization rate of nonresponders during the first 45 days (79.4/100 PY). The hospitalization rate of responders fell significantly between 45 and 90 days after HAART initiation and reached a plateau at approximately 45/100 PY from 91 to 365 days after HAART initiation. Significant decreases were seen in hospitalizations for opportunistic and nonopportunistic infections.

Conclusions: The first substantial clinical benefit from HAART may be realized by 90 days after HAART initiation; providers should keep close vigilance at least until this time.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: RDM has been a consultant for Bristol-Myers Squibb and GlaxoSmithKline and has received research funding from Merck, Pfizer, and Gilead. KAG has been a consultant for Tibotec and has also received research funding unrelated to this project from Tibotec. Both other authors: no conflicts.

Figures

Fig. 1
Fig. 1
Hospitalization rates for virological responders and nonresponders prior to and over the first year following highly active antiretroviral therapy (HAART) initiation. *Indicates P < 0.05 for the relative rate (RR) vs. days 1–45 for responders; †indicates P < 0.05 for the RR for responders vs. nonresponders within the time period. ‘Prior’ is 180 days preceding HAART initiation. n, number of persons observed within each time period. PY, person-years.
Fig. 2
Fig. 2
Hospitalization rates for the top seven diagnostic categories prior to and over the first year following highly active antiretroviral therapy (HAART) initiation. (a) Virological responders. *Indicates P < 0.05 for the relative rate (RR) vs. days 1–45; hatched areas indicate the portion of AIDS-defining illnesses (ADIs) attributed to immune reconstitution inflammatory syndromes. (b) Nonresponders. #Indicates P between 0.05 and 0.15 for the RR vs. days 1–45; †indicates P < 0.05 for the RR vs. the 180 days prior to HAART initiation, which was used as the referent for cardiovascular admissions among nonresponders as there were no admissions for this group during days 1–45. Inf, infection; Psych, psychiatric; GI, gastrointestinal; CV, cardiovascular; End/Met, endocrine, nutritional, metabolic or immune.
See this image and copyright information in PMC

References

    1. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS. 2008;22:1345–1354. - PubMed
    1. Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
    1. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267–1274. - PubMed
    1. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40:609–616. - PubMed
    1. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr. 2003;34:165–173. - PubMed

Publication types